Related Experiment Video
Updated: May 7, 2026
Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
Treatment of patients referred with Peyronie's disease
Kristin Fosli Spanfelt1,2, Jakob Kristian Jakobsen1,2
1Department of Urology, Aarhus University Hospital.
Introduction:
Peyronie's disease (PD) is a benign penile disorder characterised by fibrotic plaques, leading to curvature and potential sexual dysfunction. It often coexists with diabetes, erectile dysfunction and cardiovascular disease. In Denmark, patients are referred by general practitioners (GPs) to public or private hospitals under a treatment guarantee ensuring care within 30 days.
Methods:
We conducted a retrospective study of PD patients referred by GPs to Aarhus University Hospital in 2019. Data were retrieved from the Central Denmark Region Business Intelligence Portal. Patient characteristics, plaque location, treatment strategies and surgical outcomes were analysed using REDCap and Excel.
Results:
Among 124 referred cases, 101 met the inclusion criteria. After evaluation by a urology specialist, 44 (43.5%) were referred for surgical treatment; 29 (28.7%) were managed surgically in the public sector. Bilateral plaques were more often treated conservatively. Only 14.8% were referred for private sector treatment.
Conclusions:
GPs effectively triage PD cases for specialist care. Most patients were treated within the public sector despite capacity constraints. While the treatment guarantee may challenge healthcare sustainability, current referral patterns remain balanced.
Funding:
None.
Trial Registration:
Not applicable. The study received approval from the relevant local authorities.
More Related Videos
03:55Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis
Published on: October 18, 2024
04:22Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:27Peripheral Artery Disease III: Interprofessional Care